Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study.
Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth G, Joner M, Toelg R, Wiemer M, Olivecrona G, Vermeersch P, Garcia-Garcia HM, Waksman R. Haude M, et al. Among authors: vermeersch p. EClinicalMedicine. 2023 Apr 17;59:101940. doi: 10.1016/j.eclinm.2023.101940. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37113674 Free PMC article.
A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study.
Teeuwen K, Adriaenssens T, Van den Branden BJ, Henriques JP, Van der Schaaf RJ, Koolen JJ, Vermeersch PH, Bosschaert MA, Tijssen JG, Suttorp MJ. Teeuwen K, et al. Among authors: vermeersch ph. Trials. 2012 Dec 15;13:240. doi: 10.1186/1745-6215-13-240. Trials. 2012. PMID: 23241457 Free PMC article. Clinical Trial.
Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.
Haude M, Erbel R, Erne P, Verheye S, Degen H, Böse D, Vermeersch P, Wijnbergen I, Weissman N, Prati F, Waksman R, Koolen J. Haude M, et al. Among authors: vermeersch p. Lancet. 2013 Mar 9;381(9869):836-44. doi: 10.1016/S0140-6736(12)61765-6. Lancet. 2013. PMID: 23332165 Clinical Trial.
Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.
Van den Branden BJ, Teeuwen K, Koolen JJ, van der Schaaf RJ, Henriques JP, Tijssen JG, Kelder JC, Vermeersch PH, Rensing BJ, Suttorp MJ. Van den Branden BJ, et al. Among authors: vermeersch ph. EuroIntervention. 2013 Nov;9(7):841-53. doi: 10.4244/EIJV9I7A138. EuroIntervention. 2013. PMID: 23628457 Free article.
Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.
Teeuwen K, Van den Branden BJ, Koolen JJ, van der Schaaf RJ, Henriques JP, Tijssen JG, Kelder JC, Vermeersch PH, Rensing BJ, Suttorp MJ. Teeuwen K, et al. Among authors: vermeersch ph. EuroIntervention. 2015 Mar;10(11):1272-5. doi: 10.4244/EIJY14M08_07. EuroIntervention. 2015. PMID: 25136884 Free article. Clinical Trial.
Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium.
Riegger J, Byrne RA, Joner M, Chandraratne S, Gershlick AH, Ten Berg JM, Adriaenssens T, Guagliumi G, Godschalk TC, Neumann FJ, Trenk D, Feldman LJ, Steg PG, Desmet W, Alfonso F, Goodall AH, Wojdyla R, Dudek D, Philippi V, Opinaldo S, Titova A, Malik N, Cotton J, Jhagroe DA, Heestermans AA, Sinnaeve P, Vermeersch P, Valina C, Schulz C, Kastrati A, Massberg S; Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators. Riegger J, et al. Among authors: vermeersch p. Eur Heart J. 2016 May 14;37(19):1538-49. doi: 10.1093/eurheartj/ehv419. Epub 2015 Aug 30. Eur Heart J. 2016. PMID: 26761950 Free PMC article.
Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.
Haude M, Erbel R, Erne P, Verheye S, Degen H, Vermeersch P, Weissman N, Prati F, Bruining N, Waksman R, Koolen J. Haude M, et al. Among authors: vermeersch p. EuroIntervention. 2016 Jun 12;12(2):e160-6. doi: 10.4244/EIJ-D-15-00371. EuroIntervention. 2016. PMID: 27290675 Free article. Clinical Trial.
Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
Teeuwen K, van der Schaaf RJ, Adriaenssens T, Koolen JJ, Smits PC, Henriques JP, Vermeersch PH, Tjon Joe Gin RM, Schölzel BE, Kelder JC, Tijssen JG, Agostoni P, Suttorp MJ. Teeuwen K, et al. Among authors: vermeersch ph. JACC Cardiovasc Interv. 2017 Jan 23;10(2):133-143. doi: 10.1016/j.jcin.2016.10.017. JACC Cardiovasc Interv. 2017. PMID: 28104206 Free article. Clinical Trial.
372 results